|
KMID : 0383820130740030129
|
|
Tuberculosis and Respiratory Diseases
2013 Volume.74 No. 3 p.129 ~ p.133
|
|
|
Repeated Favorable Responses to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in a Case of Advanced Lung Adenocarcinoma
|
|
Kim Eun-Young
Kim Yoon-Hee
Ban Hee-Jung
Oh In-Jae
Kwon Yong-Soo
Kim Kyu-Sik
Kim Yu-Il
Lim Sung-Chul
Kim Young-Chul
|
|
|
Abstract
|
|
|
|
The presence of epidermal growth factor receptor (EGFR) mutation is a prognostic and predictive marker for EGFR-tyrosine kinase inhibitor (TKI) therapy. However, inevitably, relapse occurs due to the development of acquired resistance, such as T790M mutation. We report a case of repeated responses to EGFR-TKIs in a never-smoked woman with adenocarcinoma. After six cycles of gemcitabine and cisplatin, the patient was treated by gefitinib for 4 months until progression. Following the six cycles of third-line pemetrexed, gefitinib retreatment was initiated and continued with a partial response for 6 months. After progression, she was recruited for an irreversible EGFR inhibitor trial, and the time to progression was 11 months. Although EGFR direct sequencing on the initial diagnostic specimen revealed a wild-type, we performed a rebiopsy from the progressed subcarinal node at the end of the trial. The result of peptide nucleic acid clamping showed L858R/L861Q.
|
|
|
KEYWORD
|
|
|
Adenocarcinoma, Receptor, Epidermal Growth Factor, Gefitinib
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
  
|